QPOLE: A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction
暂无分享,去创建一个
J. Khattra | J. McAlpine | C. Gilks | T. van Wezel | T. Bosse | N. T. Ter Haar | M. Brinkhuis | V. Smit | N. Horeweg | G. Ortoft | C. Høgdall | E. Høgdall | C. Creutzberg | J. Jobsen | M. Haverkort | L. Lutgens | L. Vermij | S. Roothaan | Nanda Horeweg | A. S. V. M. van den Heerik | A. Léon-Castillo | Anne Sophie V M Van den Heerik | Natalja T Ter Haar | Lisa Vermij | Jan J Jobsen | Mariel Brinkhuis | Suzan M Roothaan | Alicia Leon-Castillo | Gitte Ortoft | Estrid Hogdall | Claus Hogdall | Tom Van Wezel | Ludy C H W Lutgens | Marie A D Haverkort | Jas Khattra | Jessica N McAlpine | Carien L Creutzberg | Vincent T H B M Smit | C Blake Gilks | Tjalling Bosse | N. T. ter Haar
[1] T. Werner,et al. The time is now to start molecular subtyping high-intermediate and high-risk endometrial cancers , 2022, International Journal of Gynecological Cancer.
[2] J. Ledermann,et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] P. Pollock,et al. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial , 2022, Modern Pathology.
[4] T. Bosse,et al. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment. , 2022, Gynecologic oncology.
[5] Hyojin Kim,et al. Clinical evaluation of a droplet digital PCR assay for detecting POLE mutations and molecular classification of endometrial cancer , 2021, Journal of gynecologic oncology.
[6] David F. Steiner,et al. Prospective molecular classification of endometrial carcinomas: institutional implementation, practice, and clinical experience , 2021, Modern Pathology.
[7] R. Buckanovich,et al. Cost-effectiveness analysis of tumor molecular classification in high-risk early-stage endometrial cancer. , 2021, Gynecologic oncology.
[8] A. Talhouk,et al. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta‐analysis , 2021, Cancer.
[9] Qi Wang,et al. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019. , 2021, Gynecologic oncology.
[10] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[11] Cyrus Chargari,et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma , 2020, International Journal of Gynecological Cancer.
[12] H. Putter,et al. Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial. , 2020, International journal of radiation oncology, biology, physics.
[13] H. Putter,et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer , 2020, International Journal of Gynecological Cancer.
[14] C. Gilks,et al. Interpretation of somatic POLE mutations in endometrial carcinoma , 2019, The Journal of pathology.
[15] M. Köbel,et al. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies , 2019, The Journal of pathology.
[16] T. Bosse,et al. Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial. , 2018, Gynecologic oncology.
[17] A. Talhouk,et al. Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer , 2017, Cancer.
[18] A. Talhouk,et al. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. , 2015, Gynecologic oncology.
[19] H. Morreau,et al. Assessment of a fully automated high-throughput DNA extraction method from formalin-fixed, paraffin-embedded tissue for KRAS, and BRAF somatic mutation analysis. , 2013, Experimental and molecular pathology.
[20] Tom H. Pringle,et al. The human genome browser at UCSC. , 2002, Genome research.